Abstract
Objective: to evaluate the rate of healing in diabetic foot ulcers treated with a biomembrane of latex proteins from Calotropis procera (BioMem CpLP) when compared to powdered hydrocolloid. Method: randomized controlled clinical trial, registered by the Brazilian Clinical Trial Registry (REBEC), according to protocol RBR-98f3j9, carried out with eight people with diabetic foot, in a diabetic foot clinic, from March to July 2019. In the experimental group (n = 04), biomembrane was applied; in the control group (n = 04), hydrocolloid powder was used. The healing rate was assessed at 30 and 60 days after starting treatment. Results: no statistical differences were found between the healing rates of the control group and the experimental group in the temporal analysis of the initial 30 days (p = 0.726) and in the 60 days following the start of treatment (p = 0.562). Conclusion: BioMem CpLP presented healing rates similar to the conventional product, being an effective and low cost alternative for the treatment of diabetic feet.
Highlights
Diabetes mellitus (DM) is a metabolic disease, characterized by the maintenance of high plasma glucose levels
Diabetic foot is a complication of DM and is configured as an important health problem at national and international level, and is associated with important complications, such as chronic ulcers, infections, amputations, as well as high mortality rates and the exacerbated cost in the health systems, varying in each geographic region of the planet[2]
35 people with type 2 diabetes and plantar injuries were undergoing treatment at the referred clinic. 20 people were recruited by invitation during the nursing consultation and, after acceptance, 8 were randomly allocated to the experimental group (EG) and received treatment with BioMem CpLP; and 12 in the control group (CG), in which powdered hydrocolloid was used
Summary
Diabetes mellitus (DM) is a metabolic disease, characterized by the maintenance of high plasma glucose levels. These high levels occur due to the body’s incompetence in the production, secretion and/or action of insulin and cause several problems[1]. The direct medical costs for treating this condition, in Brazil, in 2014, were US $ 361 million, considering the exchange rate of 1.74 BRL, totaling 0.31% of public health expenses for the time frame. Of this amount, 27.7 million (13%) were destined for hospitalization and 333.5 million (87%) for the outpatient segment[3]. The cost of these inputs is still far from the broad access of the low-income population and incompatible with the budget of the Unified Health System (Sistema Único de Saúde- SUS)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
